Viking Therapeutics Inc has a consensus price target of $71.43, established from looking at the 55 latest analyst ratings. The last 3 analyst ratings were released from Morgan Stanley, HC Wainwright & Co., and Truist Securities on June 27, 2024, June 24, 2024, and June 17, 2024. With an average price target of $105 between Morgan Stanley, HC Wainwright & Co., and Truist Securities, there's an implied 97.74% upside for Viking Therapeutics Inc from these 3 analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
06/27/2024 | Buy Now | 97.74% | Morgan Stanley | Michael Ulz | → $105 | Initiates | → Overweight | Get Alert |
06/24/2024 | Buy Now | 69.49% | HC Wainwright & Co. | Joseph Pantginis | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
06/17/2024 | Buy Now | 125.99% | Truist Securities | Joon Lee | $120 → $120 | Maintains | Buy | Get Alert |
06/04/2024 | Buy Now | — | Raymond James | Steven Seedhouse | — | Reiterates | → Strong Buy | Get Alert |
06/04/2024 | Buy Now | 125.99% | Maxim Group | Naz Rahman | $120 → $120 | Reiterates | Buy → Buy | Get Alert |
06/04/2024 | Buy Now | 69.49% | HC Wainwright & Co. | Joseph Pantginis | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
05/16/2024 | Buy Now | 125.99% | Truist Securities | Joon Lee | → $120 | Reiterates | Buy → Buy | Get Alert |
05/16/2024 | Buy Now | 118.46% | Raymond James | Steven Seedhouse | $115 → $116 | Upgrade | Outperform → Strong Buy | Get Alert |
04/25/2024 | Buy Now | 69.49% | HC Wainwright & Co. | Joseph Pantginis | → $90 | Reiterates | Buy → Buy | Get Alert |
03/27/2024 | Buy Now | 159.89% | Oppenheimer | Jay Olson | $116 → $138 | Maintains | Outperform | Get Alert |
03/26/2024 | Buy Now | 159.89% | Oppenheimer | Jay Olson | $116 → $138 | Maintains | Outperform | Get Alert |
03/26/2024 | Buy Now | 135.4% | BTIG | Justin Zelin | $100 → $125 | Maintains | Buy | Get Alert |
03/26/2024 | Buy Now | 69.49% | HC Wainwright & Co. | Joseph Pantginis | → $90 | Reiterates | Buy → Buy | Get Alert |
03/15/2024 | Buy Now | 125.99% | Maxim Group | Naz Rahman | → $120 | Reiterates | Buy → Buy | Get Alert |
03/15/2024 | Buy Now | 50.66% | Stifel | Annabel Samimy | → $80 | Reiterates | Buy → Buy | Get Alert |
03/15/2024 | Buy Now | 88.32% | BTIG | Justin Zelin | $86 → $100 | Maintains | Buy | Get Alert |
03/15/2024 | Buy Now | 69.49% | HC Wainwright & Co. | Joseph Pantginis | → $90 | Reiterates | Buy → Buy | Get Alert |
03/08/2024 | Buy Now | 69.49% | HC Wainwright & Co. | Joseph Pantginis | → $90 | Reiterates | Buy → Buy | Get Alert |
03/07/2024 | Buy Now | 107.16% | Jefferies | Roger Song | → $110 | Initiates | → Buy | Get Alert |
02/29/2024 | Buy Now | 125.99% | Truist Securities | Joon Lee | $32 → $120 | Maintains | Buy | Get Alert |
02/28/2024 | Buy Now | 118.46% | Oppenheimer | Jay Olson | $46 → $116 | Maintains | Outperform | Get Alert |
02/27/2024 | Buy Now | 116.57% | Raymond James | Steven Seedhouse | $37 → $115 | Maintains | Outperform | Get Alert |
02/27/2024 | Buy Now | 69.49% | HC Wainwright & Co. | Joseph Pantginis | $33 → $90 | Maintains | Buy | Get Alert |
02/14/2024 | Buy Now | -34.09% | Stifel | Annabel Samimy | $30 → $35 | Maintains | Buy | Get Alert |
02/08/2024 | Buy Now | -5.84% | Maxim Group | Naz Rahman | $35 → $50 | Maintains | Buy | Get Alert |
12/04/2023 | Buy Now | -39.74% | Truist Securities | Joon Lee | → $32 | Reiterates | Buy → Buy | Get Alert |
10/02/2023 | Buy Now | -39.74% | Truist Securities | Joon Lee | → $32 | Reiterates | Buy → Buy | Get Alert |
08/08/2023 | Buy Now | -43.5% | Stifel | Annabel Samimy | → $30 | Reiterates | → Buy | Get Alert |
07/27/2023 | Buy Now | -37.85% | HC Wainwright & Co. | Joseph Pantginis | → $33 | Reiterates | Buy → Buy | Get Alert |
06/27/2023 | Buy Now | -39.74% | Truist Securities | Joon Lee | → $32 | Reiterates | Buy → Buy | Get Alert |
05/31/2023 | Buy Now | -39.74% | Roth MKM | Dylan Dupuis | → $32 | Assumes | → Buy | Get Alert |
05/17/2023 | Buy Now | -30.32% | Raymond James | Steven Seedhouse | $35 → $37 | Maintains | Outperform | Get Alert |
05/16/2023 | Buy Now | -24.67% | Oppenheimer | Jay Olson | $35 → $40 | Maintains | Outperform | Get Alert |
05/16/2023 | Buy Now | -43.5% | Stifel | Annabel Samimy | $25 → $30 | Maintains | Buy | Get Alert |
05/16/2023 | Buy Now | -32.2% | BTIG | Justin Zelin | $31 → $36 | Maintains | Buy | Get Alert |
05/08/2023 | Buy Now | -37.85% | HC Wainwright & Co. | Joseph Pantginis | → $33 | Reiterates | → Buy | Get Alert |
05/03/2023 | Buy Now | -54.8% | Roth MKM | Scott Henry | $19 → $24 | Maintains | Buy | Get Alert |
04/27/2023 | Buy Now | -34.09% | Oppenheimer | Jay Olson | → $35 | Reiterates | → Outperform | Get Alert |
04/27/2023 | Buy Now | -37.85% | HC Wainwright & Co. | Joseph Pantginis | $21 → $33 | Maintains | Buy | Get Alert |
04/25/2023 | Buy Now | -34.09% | Oppenheimer | Jay Olson | $30 → $35 | Maintains | Outperform | Get Alert |
03/29/2023 | Buy Now | -64.22% | Roth MKM | Matt Koranda | $15 → $19 | Maintains | Buy | Get Alert |
03/29/2023 | Buy Now | -52.92% | Maxim Group | Anthony Vendetti | $15 → $25 | Maintains | Buy | Get Alert |
03/29/2023 | Buy Now | -39.74% | Truist Securities | Joon Lee | $28 → $32 | Maintains | Buy | Get Alert |
03/29/2023 | Buy Now | -34.09% | Raymond James | Steven Seedhouse | $12 → $35 | Maintains | Outperform | Get Alert |
03/29/2023 | Buy Now | -41.62% | BTIG | Justin Zelin | $20 → $31 | Maintains | Buy | Get Alert |
03/28/2023 | Buy Now | -43.5% | Oppenheimer | Jay Olson | $20 → $30 | Maintains | Outperform | Get Alert |
03/28/2023 | Buy Now | -52.92% | Stifel | Annabel Samimy | $22 → $25 | Maintains | Buy | Get Alert |
03/17/2023 | Buy Now | -58.57% | Stifel | Annabel Samimy | → $22 | Initiates | → Buy | Get Alert |
02/09/2023 | Buy Now | -77.4% | Raymond James | Steven Seedhouse | $11 → $12 | Maintains | Outperform | Get Alert |
02/09/2023 | Buy Now | -60.45% | HC Wainwright & Co. | Joseph Pantginis | → $21 | Reiterates | → Buy | Get Alert |
12/20/2022 | Buy Now | -71.75% | Maxim Group | Naz Rahman | $10 → $15 | Maintains | Buy | Get Alert |
10/27/2022 | Buy Now | -79.28% | Raymond James | Steven Seedhouse | $10 → $11 | Maintains | Outperform | Get Alert |
04/28/2022 | Buy Now | -77.4% | SVB Leerink | Thomas Smith | $18 → $12 | Maintains | Outperform | Get Alert |
02/10/2022 | Buy Now | -81.17% | Raymond James | Steven Seedhouse | $13 → $10 | Maintains | Outperform | Get Alert |
07/29/2021 | Buy Now | -75.52% | Raymond James | Steven Seedhouse | — | Maintains | Outperform | Get Alert |
The latest price target for Viking Therapeutics (NASDAQ:VKTX) was reported by Morgan Stanley on June 27, 2024. The analyst firm set a price target for $105.00 expecting VKTX to rise to within 12 months (a possible 97.74% upside). 29 analyst firms have reported ratings in the last year.
The latest analyst rating for Viking Therapeutics (NASDAQ:VKTX) was provided by Morgan Stanley, and Viking Therapeutics initiated their overweight rating.
The last upgrade for Viking Therapeutics Inc happened on May 16, 2024 when Raymond James raised their price target to $116. Raymond James previously had an outperform for Viking Therapeutics Inc.
There is no last downgrade for Viking Therapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Viking Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Viking Therapeutics was filed on June 27, 2024 so you should expect the next rating to be made available sometime around June 27, 2025.
While ratings are subjective and will change, the latest Viking Therapeutics (VKTX) rating was a initiated with a price target of $0.00 to $105.00. The current price Viking Therapeutics (VKTX) is trading at is $53.10, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.